Equities

D.Western Therapeutics Institute Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

D.Western Therapeutics Institute Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)98.00
  • Today's Change-2.00 / -2.00%
  • Shares traded540.30k
  • 1 Year change-30.00%
  • Beta1.2444
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.

  • Revenue in JPY (TTM)419.76m
  • Net income in JPY-1.06bn
  • Incorporated1999
  • Employees21.00
  • Location
    D.Western Therapeutics Institute Inc1-18-11, NishikiNAGOYA-SHI 460-0003JapanJPN
  • Phone+81 522188785
  • Fax+81 522021866
  • Websitehttps://dwti.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Veritas In Silico Inc95.43m-376.29m3.22bn19.00--1.67--33.72-58.00-58.0014.71296.600.0442----5,022,579.00-17.42---17.81-------394.31--31.68--0.00---45.99---815.45------
FunPep Co Ltd2.94m-1.56bn3.41bn15.00--1.59--1,160.55-44.48-44.480.081552.710.0010.0467--195,733.30-51.62-28.60-60.65-30.4039.68---53,241.21-3,042.404.60-608.880.00--1,056.04-54.124.75---2.98--
NPT Co Ltd0.00-266.47m3.41bn6.00--43.82-----54.98-54.980.0015.980.00-------318.44---439.04-------------2,152.880.00-------68.67------
Human Metabolome Technologies Inc1.37bn194.67m4.14bn62.0021.752.3513.593.0232.1832.18236.21297.910.63958.698.8622,148,600.009.0710.5411.0113.5961.4266.6514.1817.244.81230.200.060120.988.125.405.42--33.68--
Ribomic Inc0.00-1.05bn4.51bn25.00--1.32-----23.81-23.810.0063.040.00----0.00-31.15-29.95-32.30-31.15-------2,725.9525.20--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.06bn5.16bn14.00--1.75-----27.71-27.710.0033.640.00----0.00-66.07-35.65-74.94-36.83-------1,981.18----0.0888------44.90---67.80--
D.Western Therapeutics Institute Inc419.76m-1.06bn5.43bn21.00--3.63--12.92-24.98-24.989.4827.560.19210.41942.7119,988,760.00-48.31-24.39-52.24-26.5889.7593.00-251.53-142.258.69-274.870.2606--10.09-4.07-58.82------
Carna Biosciences, Inc.544.45m-2.19bn5.97bn63.00--6.91--10.97-114.83-114.8328.5445.150.24131.127.388,642,000.00-97.06-27.56-106.60-31.6268.3987.57-402.24-93.048.23--0.3498---60.87-27.64-88.97---20.85--
Cyfuse Biomedical KK-100.00bn-100.00bn6.53bn21.00--2.20----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m6.58bn25.00--1.60--921.44-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
TMS Co Ltd0.00-670.20m6.60bn18.00--2.20-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
PRISM BioLab Co Ltd677.33m-833.70m7.09bn35.00--2.61--10.47-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
OncoTherapy Science, Inc.956.86m-824.72m7.53bn47.00--4.11--7.87-2.90-2.903.384.860.54946.2421.5020,358,640.00-47.35-63.66-58.01-77.438.44-0.3852-86.19-184.758.21-567.860.0139--22.9318.8636.71---70.80--
Linical Co Ltd9.87bn-1.19bn7.77bn598.00--1.17--0.787-52.52-52.52437.00267.760.6226--3.6916,505,640.00-7.482.59-13.504.1921.6129.24-12.023.74----0.258477.26-15.20-0.9283-259.37---42.014.24
Medinet Co Ltd810.29m-1.36bn7.97bn107.00--2.10--9.84-5.15-5.153.0614.270.162814.023.357,572,813.00-27.37-22.42-28.82-23.6413.5417.68-168.10-173.5915.28--0.00--5.440.6867-6.67--10.06--
Chiome Bioscience Inc727.99m-905.53m8.06bn47.00--6.31--11.07-13.44-13.4410.8918.370.44896.2313.4515,489,230.00-55.84-50.30-70.30-59.7357.3356.21-124.39-190.325.37-728.130.0597--14.4111.7716.33------
Data as of Feb 06 2026. Currency figures normalised to D.Western Therapeutics Institute Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.